Core Viewpoint - PCI Biotech Holding ASA is proposing to dissolve the company and delist its shares from Euronext Oslo Børs due to the absence of operational activity and the expectation that such activity will not resume [2][3]. Group 1: Company Dissolution - The Board of Directors has proposed the resolution to dissolve PCI Biotech as there is no longer any operational activity within the company [2]. - The wholly owned subsidiary, PCI Biotech AS, has also resolved to initiate a parallel dissolution process [2]. Group 2: Delisting from Euronext Oslo Børs - The proposed resolution to delist the shares is based on the lack of operational activity and a limited asset base, leading the Board to conclude that the company is no longer suitable for public trading [3]. - The Board recommends that the delisting should occur as soon as possible [3].

Core Viewpoint - ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, enhancing strategic flexibility and reducing financial obligations related to potential change of control events [2][3]. Financial Terms - The change of control payment has been reduced from $750 million to $150 million until the end of 2027, and to $200 million thereafter [2][6]. - HealthCare Royalty will continue to receive royalties on sales by any acquirer until the original royalty cap is reached [2]. - HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, exercisable until December 31, 2030, with a lock-up period until the end of 2027 [2][3]. Product Overview - ZYNLONTA is a CD19-directed antibody drug conjugate that targets and kills tumor cells by delivering a potent payload that binds to DNA [5]. - The FDA and EMA have approved ZYNLONTA for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [7][9]. Market Potential - ADC Therapeutics anticipates significant growth for ZYNLONTA starting in 2027, with potential peak revenue in the U.S. estimated to reach between $600 million to $1 billion annually, assuming compendia inclusion and regulatory approval [3]. - The confidence in ZYNLONTA's potential is bolstered by existing and upcoming clinical data, particularly in diffuse large B-cell lymphoma and other indolent lymphomas [3]. Company Background - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates, focused on transforming treatment for patients through its portfolio, including ZYNLONTA [8]. - The company is headquartered in Lausanne, Switzerland, with operations in New Jersey, and is committed to driving innovation in ADC development [10].

Core Viewpoint - Rail Vision Ltd. has regained compliance with Nasdaq's minimum bid price requirement after its stock price was above $1.00 for 10 consecutive business days, resolving a previous non-compliance issue [1][2][3]. Company Overview - Rail Vision is an early commercialization stage technology company focused on enhancing railway safety and the rail data market through advanced artificial intelligence technology [4]. - The company's technology aims to save lives, increase efficiency, and significantly reduce costs for railway operators, while also contributing to the potential realization of autonomous trains [4].

Core Insights - North Media announced preliminary, unaudited financial results for 2025 and provided financial guidance for 2026 [1] Financial Performance for 2025 - Revenue for 2025 was DKK 1,296 million, aligning with the latest guidance of DKK 1,270 – 1,305 million [2] - EBITDA for 2025 was DKK 125 million, down 19% from the previous year, primarily due to integration costs of SDR and lower revenue in FK Distribution [2] - EBIT for 2025 was DKK 66 million, an improvement from DKK -75 million in 2024, with an EBIT margin of 5.2% [2] Segment Performance - In the Last Mile segment, revenue decreased by 1% to DKK 1,132 million, attributed to a decline in FK Distribution's volume, while SDR's revenue increased by 2% [2] - In the Digital Services segment, revenue grew by 1% to DKK 164 million, driven by a 4% increase in BoligPortal, despite a 13% decline in Dayli [3] - EBITDA in Digital Services improved to DKK 9 million from DKK -11 million in 2024, with EBIT rising to DKK 4 million from DKK -17 million in 2024 [3] Cost and Dividend Proposal - Unallocated costs for the Group were DKK 23 million, consistent with 2024 [4] - The Board proposed a dividend of DKK 1.25 per share, reflecting earnings from ordinary operations [4] Financial Guidance for 2026 - Revenue for 2026 is expected to be in line with 2025, with flat development in Last Mile and growth anticipated in Digital Services [5] - An increase in EBITDA and EBIT is expected across all companies, driven by strategic initiatives implemented in 2025 [5] - The annual report for 2025 is scheduled for publication on 25 February 2026 [5] Company Overview - North Media operates platforms that connect businesses and consumers, focusing on two core business areas: Last Mile and Digital Services [8] - Last Mile includes FK Distribution and SDR, leading distributors of leaflets and local newspapers in Denmark and Sweden [8] - Digital Services encompasses BoligPortal, Dayli, and Bekey, with potential for strong growth and scalability [8]

Company Overview - C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation (TPD) science to create innovative medicines that can transform patients' lives [3] - The company is developing targeted oncology programs through clinical studies and utilizes its TORPEDO platform to design and optimize small-molecule medicines for challenging diseases [3] - C4T's degrader medicines aim to leverage the body's natural protein recycling system to degrade disease-causing proteins, potentially addressing drug resistance and improving patient outcomes [3] Upcoming Events - C4T management will participate in the Barclays 28 Annual Global Healthcare Conference on March 10, 2026, at 8:00 AM ET in Miami, Florida, featuring a fireside chat [2] - The company will also present at the TD Cowen 46 Annual Healthcare Conference on March 3, 2026, at 11:50 AM ET in Boston, Massachusetts, where management will engage in a fireside chat [4]

Core Insights - Kraig Biocraft Laboratories, Inc. is recognized for its advancements in spider silk technology, featured on the cover of National Geographic's March 2026 issue [1][13] Group 1: Company Achievements - The article highlights Kraig Labs' innovative approach to producing spider silk fibers using genetically enhanced silkworms, emphasizing its cost-efficiency and high quality [2] - Kraig Labs' recombinant spider silk technology has been tested successfully, demonstrating its strength by towing a car and suspending a person from the ceiling with a single 0.35-ounce loop of thread [4] - The recognition by National Geographic marks a significant milestone for Kraig Labs and the biomaterials innovation sector [3] Group 2: Commercialization and Market Potential - The feature discusses the scalability of silkworm cultivation combined with the performance properties of spider silk, indicating growing commercial opportunities for spider silk biomaterials [2] - Kraig Labs is preparing to ramp up production operations to meet the increasing market demand for high-performance, sustainable fiber and fabric solutions [6]

Core Viewpoint - uniQure N.V. is set to report its fourth quarter and full year 2025 financial results on March 2, 2026, highlighting its ongoing commitment to advancing gene therapies for severe medical conditions [1]. Group 1: Financial Reporting - The financial results will be announced before market open on March 2, 2026, followed by a conference call at 8:00 a.m. ET [1]. - The event will be accessible via webcast on uniQure's website, with a replay available for 90 days post-event [2]. Group 2: Company Overview - uniQure is recognized for its pioneering work in gene therapy, particularly for hemophilia B, marking a significant milestone in genomic medicine [3]. - The company is advancing a pipeline of proprietary gene therapies targeting conditions such as Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease, among others [3].

Pet Valu’s family of stores providing fifteen grand prizes of dry dog or cat food for one year and 17,000 $15 in store e-gift cards MARKHAM, Ontario, Feb. 23, 2026 (GLOBE NEWSWIRE) -- For the first time since Tim Hortons launched Roll Up To Win™ 40 years ago, Canadians playing the iconic contest will have the chance to win Pet Valu prizes for their pets. Pet Valu, Canada’s leading specialty retailer of pet food and pet-related supplies, announced today that it is the contest’s first-ever pet retail prize pa ...

Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $ ...

(All amounts in US$ unless otherwise stated) TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) today announced that its Board of Directors has approved a $73 million construction budget and established an execution schedule to achieve mechanical completion of its cobalt sulfate Refinery north of Toronto, marking a significant step toward bringing North America’s first battery-grade cobalt refinery into operation. Commiss ...